IL-33 is an important inflammatory mediator in allergy, asthma, and joint inflammation, acting via its receptor, ST2L, to elicit Th 2 cell cytokine secretion. IL-33 is related to IL-1 and IL-18, which both influence bone metabolism, IL-18 in particular inhibiting osteoclast formation and contributing to PTH bone anabolic actions. We found IL-33 immunostaining in osteoblasts in mouse bone and IL-33 mRNA expression in cultured calvarial osteoblasts, which was elevated by treatment with the bone anabolic factors oncostatin M and PTH. IL-33 treatment strongly inhibited osteoclast formation in bone marrow and spleen cell cultures but had no effect on osteoclast formation in receptor activator of nuclear factor-B ligand/macrophage colony-stimulating factor-treated bone marrow macrophage (BMM) or RAW264.7 cultures, suggesting a lack of direct action on immature osteoclast progenitors. However, osteoclast formation from BMM was inhibited by IL-33 in the presence of osteoblasts, T cells, or mature macrophages, suggesting these cell types may mediate some actions of IL-33. In bone marrow cultures, IL-33 induced mRNA expression of granulocyte macrophage colony-stimulating factor, IL-4, IL-13, and IL-10; osteoclast inhibitory actions of IL-33 were rescued only by combined antibody ablation of these factors. In contrast to osteoclasts, IL-33 promoted matrix mineral deposition by long-term ascorbate treated primary osteoblasts and reduced sclerostin mRNA levels in such cultures after 6 and 24 h of treatment; sclerostin mRNA was also suppressed in IL-33-treated calvarial organ cultures. In summary, IL-33 stimulates osteoblastic function in vitro but inhibits osteoclast formation through at least three separate mechanisms. Autocrine and paracrine actions of osteoblast IL-33 may thus influence bone metabolism.
B one structure and metabolism are determined by the formation and activity of osteoblasts and osteoclasts. These two cell types not only regulate the actions of each other but are both critically affected by local influences emanating from other cells in the bone microenvironment (1, 2) . Characterizing such influences is critical for understanding of the processes that underlie bone metabolism and to identify therapeutic targets that may enable the design of new anticatabolic and anabolic therapies for bone. One approach is to identify factors regulated by hormones that enhance bone formation, such as PTH and oncostatin M (OSM) (3, 4) , and to determine how such factors affect osteoclast and osteoblasts both directly and through the mediation of other cell types.
Preliminary results from DNA array studies of osteoblastic cells suggested to us that IL-33 and its receptor subunit ST2L (also termed IL1RL1 and IL-33R) may be a regulatory target of PTH and so may influence bone me-tabolism. IL-33 is a member of the IL-1 family of cytokines, two other members of which have well-characterized actions on bone cells. IL-1 itself is a stimulator of osteoclast activity and survival and induces osteoblast production of the critical osteoclast differentiation factor receptor activator of nuclear factor-B ligand (RANKL) (5, 6) . By contrast, we have previously found that IL-18, produced by osteoblasts and macrophages, has little or no direct effect on the osteoclasts but can indirectly elicit T cell-derived osteoclast inhibitory factors (7, 8) . IL-18 may also participate in the osteoblast-mediated anabolic effects of PTH in vivo (9) .
IL-33 arises as a 30-kDa acid protein that can undergo caspase-1 cleavage and secretion but may also function as a nuclear factor in endothelial cells in inflammatory diseases (10 -12) and as an alarmin released by dead or dying cells (13) . IL-33 shows a wide mouse and human tissue distribution (10, 14, 15) and is best characterized as a stimulator of IL-4, IL-5, and IL-13 production from Th 2 cells (14, 16) , although it also has prosecretory or chemotactic effects on mast cells, basophils, eosinophils, and dendritic cells (17) (18) (19) (20) (21) . IL-33 delivered by systemic administration and transgenic overexpression has strong proinflammatory effects (14) . IL-33 notably participates in Th 2 -mediated inflammatory processes, such as in asthma (22) , but nevertheless may also participate in pathogenic processes in which Th 1 cytokine actions predominate. Recent reports identify IL-33 in synovia of rheumatoid arthritis patients and collagen-induced arthritis models of rheumatoid arthritis, in which reducing IL-33 activity attenuated the severity of the inflammation (23) . Roles for IL-33 have been noted in ulcerative colitis, anaphylactic shock, cardiac hypertrophy, atherosclerosis, and psoriatic skin disease (24 -28) . IL-33 elicited cell signaling is similar to that of IL-1, with IL-33 receptor ST2L forming a signaling complex with IL-1R accessory protein (17, 29, 30) that evokes nuclear factor nuclear factor-B (NF-B), activator protein-1 (AP-1), c-Jun N-terminal kinase (JNK, ERK1/2 and p38 signals and increases phosphorylation of c-Jun (31) . A soluble IL-33 decoy receptor with antiinflammatory properties, ST2, arises from alternatively spliced transcripts of the Il1rl1 gene, which encodes ST2L (32, 33) . ST2 may also play a pathological role in cardiac hypertrophy and fibrosis (26) .
The role of IL-33 on such a range of pathogenic processes, several of which affect bone, and its ability to elicit Th 2 cytokines (most of which inhibit osteoclast differentiation) suggest that IL-33 production could significantly influence bone cells. There has also been a recent report of IL-33 possessing surprising RANKL-like actions in human osteoclast formation (34) . Given these considerations, we sought to clarify IL-33 actions by investigating its expression in bone cells, its regulation by PTH and OSM, and IL-33 influence on osteoblast-and osteoclast-lineage cells. We identified and characterized a number of antiosteoclastogenic and osteoblast stimulatory effects of IL-33, which indicate that this cytokine could be a significant endogenous regulator of bone cell activity and bone metabolism.
Materials and Methods
C57BL/6J mice were obtained from Monash Animal Services (Clayton, Australia), and mice were maintained at Monash Medical Centre Animal Facility (Clayton, Australia), with procedures approved by Monash Medical Centre Animal Ethics Committee B (Clayton, Australia). Cells from granulocyte macrophage colony-stimulating factor (GM-CSF) Ϫ/Ϫ (C57Bl6/J background) mice were kindly provided by Dr. Matthias Ernst (The Ludwig Institute for Cancer Research, Parkville, Australia). Cells were cultured in ␣-MEM (Life Technologies, Inc., Gaithersburg, MD) with 10% fetal bovine serum (FBS; CSL Biosciences, Parkville, Australia) and penicillin 50 U/ml, streptomycin 50 g/ml, and 2 mM L-glutamine (MEM/FBS). Recombinant glutathione-S-transferase-RANKL 158 -316 was produced using a bacterial construct kindly provided by Dr. F. Patrick Ross (Washington University School of Medicine, St. Louis, MO); human His-tagged macrophage colony-stimulating factor (M-CSF) was similarly produced and purified in-house from a bacterial construct. Other recombinant proteins were obtained from R&D Systems (Minneapolis, MN) except recombinant mouse IL-33, obtained from Axxora (San Diego, CA). 1␣,25-Dihydroxyvitamin D 3 [1,25(OH) 2 -D 3 ] was obtained from Wako Pure Chemical Co. (Osaka, Japan). Other reagents were analytical grade obtained from Sigma Chemical Co. (Castle Hill, Australia) unless noted.
Cells and assays
Spleen cells were obtained by spleen disaggregation through a fine-wire sieve (8) . Lymphocytes were extracted from spleen cells (8) by immunomagnetic Dynabeads (Invitrogen, Carlsbad, CA) coated with antibodies to B220 (B cells), Thy1.2 (pan-T cells), L3T4 (CD4 ϩ cells), or Lyt2 (CD8 ϩ cells). To purify B or T cells for use in cocultures, a negative selection kit using Dynabeads (Invitrogen) were used. Bone marrow cells were flushed from long bones with sterile saline (35) and bone marrow macrophages (BMM) prepared as previously described (35) .
Osteoblasts were prepared from newborn mice calvariae by sequential digestion with 0.1% collagenase/0.2% dispase (Godo Shusei, Tokyo, Japan) and cultured for 3-4 d until they were confluent before any use. Osteoblasts were harvested by trypsinization and seeded as required. All cell cultures used MEM/10% FBS unless noted. To investigate osteoblastic matrix mineralization, cells were seeded (2.5 ϫ 10 4 /well) in 16-mm diameter plastic tissue culture wells (Greiner, Frickenhausen, Germany) in MEM/FBS until confluent and then stimulated to differentiate with 50 g/ml ascorbate-2-phosphate, 2 mM ␤-glycerophosphate, and 10 nM dexamethasone and incubated for 21 d (36), with medium and mediators changed three times per week. In IL-33-treated cultures, IL-33 (20 ng/ml) was added from d 0 to d 21, replenished with each media change. Cells were ethanol fixed, immersed in 0.5% alizarin red (pH 4.2) for 30 min, and rinsed in PBS, and then images were taken by scanner (Epson Perfection V500; Epson Australia, North Ryde, NSW, Australia). The cells were then incubated in 10% cetylpyridinium chloride and the eluted alizarin red measured by spectrophotometer (37) .
Murine osteoclasts were generated in 10-mm diameter plastic tissue culture wells (Greiner Bio-One) seeded with 5 ϫ 10 5 spleen cells/well, 10 5 bone marrow or BMM per well, and stimulated with RANKL (100 ng/ml) and M-CSF (30 ng/ml) (35) ; RAW264.7 cells (American Type Culture Collection, Manassas, VA) were seeded 10 4 cells/well and stimulated with 50 ng/ml RANKL. Cells were fixed and histochemically stained to identify tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNC), previously validated as osteoclasts (35) . Alternatively, spleen cells or BMM was cocultured with 2 ϫ 10 4 calvarial osteoblasts or Kusa O cells (37) and 1,25(OH) 2 -D 3 (10 Ϫ8 M).
To generate human osteoclasts in vitro, human umbilical cord blood and adult peripheral blood were obtained from healthy donors under a protocol approved by Barwon Health Research and Ethics Advisory Committee. Mononuclear cell fraction from cord blood was isolated by Ficoll-Paque density gradient centrifugation in vitro, and granulocyte macrophage-colony forming unit (GM-CFU) progenitors in the mononuclear cell fraction from cord blood expanded by incubation in semisolid media containing growth factors for 14 d as previously described (38) . These expanded progenitors (4 ϫ 10 4 /well) were seeded into 6 mm diameter tissue culture wells containing 4-ϫ 4-ϫ 0.1-mm slices of sperm whale dentine as cell substrate and cultured in 200 l MEM/FBS with M-CSF (30 ng/ml) and RANKL (62.5 ng/ml) or human IL-33 (20 ng/ml). These cultures were refreshed twice weekly by replacing additives in half volume of media. Cells were fixed after 14 d in 1% formalin histochemically stained to identify TRAP (38) . Formation of osteoclasts was assessed by transmission light microscopy and quantified using microcomputer image analysis software (MCID; Imaging Research Inc., Ontario, Canada) (38) . Cells were removed from dentine slices by sonication in chloroform-methanol 2:1. Xylene-free black ink was applied to the resorbed surface of each slice and residual ink removed by wiping against absorbent paper. Resorption was assessed by transmission light microscopy (38) .
Analysis of mRNA expression
Cells for analysis were cultured in MEM/FBS on tissue culture plastic wells. Spleen and bone marrow cells were extracted in PBS, centrifuged (270 g) to pellet, and then resuspended in MEM/ FBS and incubated 5 ϫ 10 6 cells/well in 35-mm diameter wells, with the start of regulation study (0 h) beginning when cells were placed in the well. Two types of osteoblasts were used for regulation studies: unmatured osteoblasts for GM-CSF, IL-10, IL-4, IL-13, IL-33, and ST2L mRNA and matured osteoblasts (which contain osteocytic cells) for sclerostin, dentin matrix protein-1 (DMP-1) and matrix extracellular phosphoglycoprotein (MEPE) mRNA. Unmatured osteoblasts consisted of cells grown from extracted calvarial cells, which were subcultured by trypsin digestion, centrifuged to pellet, resuspended in MEM/FBS, and plated in 35-mm diameter wells, 4 ϫ 10 5 cells/well. The stimulation commenced after 1 d incubation, when cells were about 90% confluent. Matured osteoblasts containing osteocytic cells were obtained for analysis by culturing osteoblasts for 14 d in 50 g/ml ascorbate-2-phosphate and 2 mM ␤-glycerophosphate in MEM/10% FBS. This was long enough to express high mRNA levels of osteocytic cell markers sclerostin, MEPE, and DMP-1. Three hours before stimulation (0 h), medium on these cells was replaced with MEM/FBS containing 2% FBS. All hormonal mediators were added in aqueous vehicle.
RNA was isolated using TRIZOL reagent (Invitrogen, Castle Hill, Australia) according to the manufacturer's instructions. RNA was then treated with ribonuclease-free deoxyribonuclease (Roche Diagnostics, Castle Hill, Australia) for 30 min at 37 C. RNA concentration was determined by spectrophotometer (ND1000; ThermoScientific, Wilmington, DE). cDNA was synthesized [random hexamers, 10 mM deoxynucleotide triphosphate, 5 ϫ first-strand buffer, 0.1M dithiothreitol, RNaseOUT (Invitrogen), Superscript III (Invitrogen) reverse transcriptase (200 U/l)] using 5 g starting material under the following conditions: 5 min at 65 C; 5 min at 4 C; 60 min at 50 C; 15 min at 70 C; 8 min at 4 C (Bio-Rad iCycler; Hercules, CA). Real-time PCR analysis (Stratagene Mx3000P; Agilent Technologies, Forest Hill, Australia) of cDNA was performed using Platinum SYBR Green quantitative PCR supermix UDG (Invitrogen) according to the manufacturer's instructions and the following conditions: one cycle for 10 min at 95 C; 40 cycles for 30 sec at 95 C, 1 min at 60 C, 30 sec at 72 C; one cycle for 1 min at 95 C, 30 sec at 55 C, 0 sec at 95 C) normalized to hypoxanthine phosphoribosyltransferase (HPRT). Oligonucleotide primer sequences (Table 1 ) were obtained used from Primerbank (39) .
Statistical analysis
Data are shown as mean Ϯ SE unless otherwise noted. Statistical significance of differences between groups was determined by ANOVA (using Tukey's post hoc test) for multiple comparisons; where a single comparison was made, we used Student's t test. For mRNA analyses, two independent analyses were performed in triplicate on RNA from two independent experiments. Cell culture data were pooled from three or more independent experiments. Data in this manuscript were audited in accordance with the National Health and Medical Research Council 
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Results

Expression and regulation of IL-33 in bone cells
Real-time RT-PCR analysis of RNA extracted from whole spleen cell populations, primary calvarial osteoblasts, Kusa O cells, BMM, and RAW264.7 cells revealed that all of these populations expressed detectable levels of ST2L mRNA, and all but RAW264.7 cells expressed IL-33 mRNA ( Table 2 ). Immunohistochemical staining for IL-33 in sections of mouse long bone showed staining predominantly in osteoblasts and bone lining cells, with little osteocyte staining evident ( Fig. 1A) . Some immunostaining was evident among marrow cell populations and chondrocytes. IL-33 immunostaining was also evident in primary cultured osteoblasts ( Fig. 1B) .
We investigated IL-33 mRNA regulation by 10 nM PTH in primary cultured osteoblasts and confirmed that PTH treatment enhanced IL-33 mRNA levels at 6 and 24 h (Fig.  1C ). ST2L mRNA was also enhanced by PTH, although this was transient with a maximal effect at 6 h. Because we have previously seen important proanabolic responses in osteoblasts to OSM (4), we also studied the effects of this cytokine. OSM, like PTH, enhanced IL-33 mRNA levels but to a greater degree ( Fig. 1D ). Unlike PTH, OSM caused a sustained enhancement of ST2L mRNA (Fig. 1D ).
IL-33 action on osteoclast differentiation in vitro
Murine bone marrow and spleen cell populations were stimulated with a combination of RANKL (100 ng/ml) and M-CSF (30 ng/ml), which as previously demonstrated (40) generated numerous osteoclasts after 7 d of culture, evident as TRAP-positive multinucleated cells (TRAP ϩ MNC). IL-33 dose dependently inhibited TRAP ϩ MNC formation from bone marrow cells ( Fig. 2A) , an inhibitory effect exerted specifically during the earlier part (first 3 d) of the culture period ( Fig. 2B ); this is a stage of osteoclast progenitor commitment before the appearance of osteoclast markers. Oste-oclast formation from spleen cells was also dose dependently inhibited by IL-33 ( Fig. 2C ). In contrast, when RANKL stimulated RAW264.7 cells or nonadherent BMM were treated with IL-33, no such inhibition of osteoclast differentiation occurred (Fig. 2 , D and E). Such BMM constitute a highly enriched, immature macrophage/osteoclast progenitor population (35) as are RAW264.7 cells, although the latter are an immortalized murine leukemic cell line. In contrast, bone marrow cell populations are mixed cell populations that contain not only osteoclast progenitors but also other cell types, including mature macrophages, stromal cells, and lymphocytes.
Because IL-33 has recently been described as possessing RANKL-like osteoclast formation-stimulating ability in human CD14 ϩ cells, we treated M-CSF-stimulated BMM with IL-33; however, no TRAP ϩ MNC formation was evident ( Fig. 2E) . Similarly, M-CSF-and RANKL-treated human osteoclast progenitors formed large numbers of dentine-resorbing functional osteoclasts (Fig. 2 , F and G). In contrast, in response to IL-33 plus M-CSF treatment, TRAP ϩ mononuclear cells were evident, but we could locate only one possible candidate TRAP ϩ MNC and two small pits in all the dentine surfaces screened, contrasting with the thousands of pits seen consistently on dentine slices with RANKL stimulation. This suggests that IL-33 has a very weak or indirect action similar to IL-6 and TGF␤ (41, 42) , at least on these cell populations.
Indirect effects of IL-33 on osteoclast formation via T cells, macrophages, and osteoblasts
Lack of direct osteoclast inhibitory action of IL-33 on BMM and RAW264.7 cells suggested that IL-33 may exert its actions through indirect means in bone marrow and spleen cultures. Because T cells are abundant in spleen cell populations, and because IL-18 (which is structurally related to IL-33) exerts inhibitory actions via T cells, we cocultured splenic T cells with BMM and found that IL-33 greatly reduced osteoclast formation in such cultures (Fig. 3A) ; IL-33 has no actions on BMM in the absence of T lymphocytes ( Fig.  2E ). However, when splenic cell populations were depleted of T cells by immunomagnetic (Thy1.2 antibody labeled) beads, IL-33 still inhibited osteoclast formation ( Fig. 3B ); IL-12 or IL-18 were without activity in these cultures, indicating successful removal of T lymphocytes (data not shown). This suggested that some other cell type mediating IL-33 action was present in the spleen cells and that T cells are able to mediate IL-33 inhibition only when they were highly enriched and cocultured with BMM in the absence of any other mediating cells present in spleen cells. However, depleting B cells or both B and T lymphocytes had no effect, nor did addition of B lymphocytes to BMM result in IL-33 inhibitory action (data not shown). Documented IL-33 action 3C ). This suggested both that these matured macrophage populations produce an osteoclast inhibitor in response to IL-33 and also that this mediator was soluble and diffusible across the porous membrane. Because we had found that osteoblasts expressed ST2L mRNA ( Fig. 1) , suggesting IL-33 responsiveness, we investigated whether IL-33 affects osteoblast-dependent osteoclast formation, which probably constitutes the major type of osteoclast formation in vivo (1) . BMM were cocultured with calvarial osteoblasts stimulated with 1,25(OH) 2 -D 3 (which stimulates membrane bound RANKL expression in osteoblasts and suppresses osteoprotegerin production), resulting in numerous osteoclasts as previously described (44); IL-33 (20 ng/ml) treatment strongly inhibited this ( Fig. 3D ). When osteoblastic cells were separated from RANKL-stimulated BMM by permeable membrane, inhibition of osteoclast formation by IL-33 was also observed ( Fig.  3E) , again suggesting the IL-33-elicited release of a soluble osteoclast inhibitor. Note that 1,25(OH) 2 -D 3 was not added in the latter cultures to stimulate RANKL because RANKL produced by osteoblasts is membrane bound, which can not reach BMM due to the separation of the two cell types by the Transwell membrane.
Inhibitory mediators of IL-33 osteoclast inhibitory action in spleen and bone marrow cell populations
IL-33 is known to elicit the production of Th 2 cytokines IL-4, IL-13, and IL-10 as well as GM-CSF; each of these inhibit formation of osteoclasts in vitro (8, 45, 46) . In splenic cell populations, IL-33 strongly enhanced mRNA levels for each of these cytokines (Fig. 4A) ; Th 2 cytokine IL-5 mRNA was also enhanced (data not shown), although this cytokine is not an osteoclast inhibitor. Because we have previously found that IL-18 inhibits osteoclast formation predominantly via GM-CSF (8), we first investigated GM-CSF roles in mediating IL-33 effects because it also strongly enhances GM-CSF steady-state mRNA levels (Fig. 4A) . Addition of only the GM-CSF neutralizing antibody (1 g/ml) was enough to ablate the effects of IL-33 in RANKL-stimulated spleen cell cultures (Fig.   4B ), and IL-33 actions were not evident in cultures of spleen cells from GM-CSF Ϫ/Ϫ mice (Fig. 4C) , suggesting that GM-CSF is the predominant IL-33 mediator in these populations; note, however, that this does not exclude the possibility of weak actions of other IL-33 induced factors. GM-CSF when added to RANKLϩM-CSF-stimulated BMM inhibited osteoclast formation when present in the earlier part of the culture period ( Fig.  4D) , as was clearly observed with IL-33 in bone marrow cells (Fig. 2B) ; this is consistent with GM-CSF mediating (at least in part) IL-33 action in the bone marrow cultures. IL-4 acted in a similar manner (Fig. 4D) .
In bone marrow cell cultures, IL-4, IL-13, IL-10, and GM-CSF mRNA levels were, as in spleen cells, enhanced by IL-33 (20 ng/ml) treatment (Fig. 4E) . We investigated the role(s) of these cytokines in the action of IL-33 on osteoclast formation by using neutralizing antibodies to IL-4, IL-10, IL-13, and GM-CSF to determine whether any could rescue IL-33-mediated osteoclast inhibition of bone marrow progenitors. Neutralization of GM-CSF (or both IL-10 and GM-CSF) partially reduced the inhibitory action of IL-33 ( Fig. 4F ). Consistent with this, and unlike the case of splenic cells, IL-33 treatment of bone marrow from GM-CSF Ϫ/Ϫ mice resulted in partial inhibition (Fig. 4G ). IL-33 osteoclast inhibitory actions were nullified only in the presence of a combination of neutralizing antibodies (micrograms per milliliter each) to IL-4, IL-10, IL-13, and GM-CSF (Fig. 4F) .
In contrast to spleen and bone marrow populations, osteoblasts treated with IL-33 showed enhancement of only GM-CSF mRNA levels (Fig. 4H) ; IL-4 was not detectable, whereas IL-13 and IL-10 levels were not regulated (data not shown). In cocultures of BMM with 1,25(OH) 2 -D 3 -treated osteoblastic Kusa O cells (Fig. 4I ) or calvarial osteoblasts (data not shown), IL-33 action was ablated by GM-CSF neutralizing antibody (Fig. 4I) . 
IL-33 induction of dendritic cell formation via osteoblasts
GM-CSF may inhibit osteoclast formation by causing immature progenitors to commit to dendritic cell differentiation at the expense of osteoclasts or mature macrophages. Consistent with recent observations of Mayuzumi et al. (21) , we found IL-33 treatment (20 ng/ml) resulted in CD11c ϩ cell formation from RANKL/M-CSF-stimulated BMM (Fig. 5A ) in the lower chambers of the Transwell plates exposed to (but separated by porous membrane from) osteoblasts in the upper chamber ( Fig. 5A ). BMM cultured in the absence of osteoblasts were not affected by IL-33 treatment.
Other IL-33 actions on osteoblasts
Because IL-33 exerts significant effects via osteoblasts on osteoclast formation, we investigated its action on osteoblasts. IL-33 is structurally related to IL-1, which induces osteoclast formation via enhanced osteoblastic RANKL production (47) . We found that IL-33 also elevates RANKL mRNA approximately 2-fold in osteoblasts (Fig. 5B ). Stimulation of osteoblast/BMM cocultures with IL-33 in the presence of GM-CSF neutralizing antibodies did not cause the formation of any TRAP ϩ MNC formation (data not shown), indicating that the levels of RANKL enhanced by IL-33 were insufficient to invoke osteoclast formation.
We further explored IL-33 effects on osteoblast matrix mineral deposition. Longterm calvarial osteoblast cultures treated with ascorbate, dexamethasone, and ␤-glycerophosphate resulted in the formation of numerous well-defined mineralized nodules as previously described (36); IL-33 treatment (20 ng/ml) caused mineral deposition to approximately double ( Fig. 5C ; higher power view of nodules shown in Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). In these cultures, sclerostin-expressing osteocyte-like cells arise, which may affect osteoblast activity. To investigate whether IL-33 could be influencing osteoblast activity by actions on osteocyte sclerostin, we investigated this in both calvarial organ cultures ( Fig. 5D ) and long-term matured osteoblastic cultures after differentiation to mature osteoblasts (Fig.  5E ). Sclerostin is produced solely by osteocytes, and sclerostin mRNA was both readily detectable and suppressed by IL-33 treatment in both culture systems. Expression of osteocyte markers DMP-1 and MEPE mRNA levels were also investigated to give an indication of the breadth of IL-33 action on these cells. IL-33 transiently enhanced DMP-1 steady-state mRNA levels (Fig. 5E ), but there was no significant effect on MEPE steady-state mRNA levels.
Discussion
Our studies have confirmed that IL-33 and its receptor are expressed in bone cells, notably osteoblasts, and that IL-33 both enhances osteoblast-mediated matrix mineral deposition and reduces osteoclast formation. IL-33 mRNA levels in primary osteoblasts were greatly enhanced by PTH and by OSM treatment, an observation of particular interest given the significant anabolic effects that these two factors exert on bone. PTH in particular exerts several actions on osteoblast-lineage cells that together result in higher osteoblast numbers, including re- duced osteocytic sclerostin levels (48) , although PTH also enhances osteoblast RANKL expression and thereby osteoclast formation. PTH action is thus complex but much studied with a view to understanding its clinical anabolic action to identify better anabolic agents. For this reason, identification of bone-active factors targeted by PTH is clearly of interest. OSM, although less well characterized than PTH, also enhances osteoblast action and suppresses sclerostin expression (4) . Thus, the parallels between IL-33, OSM, and PTH actions on osteoblasts seem striking, especially given that the intracellular signals they use are quite different, and suggest that, like OSM and PTH, IL-33 plays a significant role in maintaining bone mass, particularly given IL-33 production in bone. There are, how-ever, numerous differences between OSM, PTH, and IL-33 actions on different cell types, making it unlikely that IL-33 mediates the others' actions but may well modify them. Because calvarial osteoblasts are such a mixture of cells at different stages of differentiation, the mechanism of IL-33 enhancement of their activity is difficult to investigate. Indeed, we did not observe IL-33 enhancement of expression of alkaline phosphatase, osteocalcin, or bone restricted ifitim-like protein, proteins conventionally used as markers of osteoblast maturation (data not shown); it should be noted, however, that their expression levels in osteoblasts rise rapidly in response to ascorbate treatment and further increases may be difficult to show as signifi- cant, unlike inhibitory effects. Nevertheless, the observed suppression of sclerostin mRNA in long-term osteoblast cultures, similar to our previous observations with OSM (4) , is highly suggestive of an influence on mature osteoblast activity. Osteocytic cells arise in these long-term cultures (evidenced by the detection of DMP-1 and MEPE), and they are a source of this osteoblast inhibitor. We saw similar suppression of sclerostin mRNA in organ cultures of intact calvaria by IL-33 treatment, indicating that bona fide osteocytes in bone respond as the cultured cells do. Sclerostin inhibits canonical Wnt signaling in osteoblasts, and, consistent with this, we noted a significant 1.9-fold increase in mRNA levels of Wnt signal target (49) Axin2 in IL-33-treated (20 ng/ml, 24 h) ascorbate matured osteoblasts (data not shown). As an inhibitor of canonical Wnt signals, sclerostin is a potent antianabolic factor in bone and recognized as a therapeutic target of great potential (48) . Other than PTH and IL-6 family members, only mechanical loading has been shown to suppress sclerostin (50) , so the discovery of IL-33 having potential to act as an osteoblast paracrine factor to reduce sclerostin adds to our knowledge of this important bone factor. In bone marrow and spleen populations, both heterogeneous populations containing hematopoietic progenitors, we found IL-33 dose dependently inhibited osteoclast formation elicited by RANKL/M-CSF stimulation and that this was evidently mediated through several mechanisms (summarized in Fig. 6 ). In osteoblast-supported cocultures, IL-33 also strongly inhibited osteoclast formation, and it is possible other related cells (such as bone marrow stromal cells) may mediate such IL-33 actions. Like OSM and PTH, IL-33 was found to (albeit weakly) enhance osteoblast RANKL, but such proosteoclastogenic effects were far weaker than its inhibitory effects. We were surprised to find that enriched M-CSF-dependent immature BMM populations derived from bone marrow were not affected in this way by IL-33, nor were RAW264.7 cells, even though both cell types expressed ST2L mRNA. We used this finding to investigate indirect actions of IL-33, as we previously observed in work with IL-18 (8) . This enabled us to confirm that IL-33 effects were exerted through osteoblasts themselves and also to identify T cell mediation of IL-33 inhibition. This may not be surprising given the role of ST2L/IL-33 in Th 2 biology; however, it could not explain IL-33 inhibition of osteoclast formation in spleen or bone marrow cells because eliminating Thy1.2 ϩ cells using immunomagnetic beads did not rescue IL-33 effects; indeed, bone marrow contains few T cells. This suggested that other cell types could participate in these effects of IL-33, and indeed, matured macrophages were identified as a candidate population. Mature adherent macrophages are abundant in marrow and spleen cultures (enhanced in their survival by the presence of M-CSF) and can be derived from BMM with prolonged incubation (35) . As BMM mature, their ability to form osteoclasts diminishes, presumably as they become committed to the macrophage lineage; indeed, the macrophages used in this study formed little or no osteoclasts with RANKL stimulation. In vivo, mature macrophages are present not only in the bone marrow but also as osteal macrophages closely associated with osteoblasts at the bone surface (51) . T cells and mature macrophages have been proposed to have a significant role in bone metabolism (51, 52) , which reinforce the notion of IL-33 as an osteoclast inhibitor. However, induction of IL-33 could potentially exert actions dependent on its known intracellular localization, either intracrine or as an alarmin released upon cell death. Our mechanistic studies of IL-33 action on osteoclast differentiation indicated it was significantly dependent on GM-CSF induction; indeed, in spleen cells and osteoblasts, the effects of IL-33 were completely rescued by a GM-CSF-neutralizing antibody. GM-CSF induction by IL-33 has been previously described (21) , and, consistent with those studies, we identified dendritic cell formation in IL-33-treated cultures. This suggests formation of dendritic cells at the expense of osteoclasts. The significance of GM-CSF on osteoclasts in vivo is, however, very unclear because GM-CSF null mice have not been reported to have abnormal bone and transgenically GM-CSF overexpressing mice have systemic inflammation, which would negatively affect bone mass. In RANKL/M-CSF-treated marrow cultures; however, GM-CSF was clearly not the only inhibitory influence, its ablation only partly rescuing osteoclast formation. Other Th 2 cytokines were, as expected, induced in these cell cultures, although they were similarly induced in spleen cell populations in which GM-CSF accounted for the inhibitory action of IL-33. Neutralizing antibodies to IL-4, IL-13, IL-10, or GM-CSF individually did not fully rescue IL-33 effects; however, in combination, these antibodies rescued IL-33 inhibitory actions on osteoclast formation.
As this manuscript was being prepared, the work of Schulze et al. (53) appeared in press, describing studies of IL-33 in bone and bone cells. This study characterized ST2 knockout mice (i.e. lacking IL-33 receptor) as having reduced trabecular bone mass (relative to wildtype controls) due to elevated osteoclast numbers; consistent with this, IL-33 expression was identified in osteoblasts and recombinant IL-33 was shown to block osteoclast formation in bone marrow cultures. Our characterization of the latter is in broad agreement with the conclusions of Schulze et al. (53) despite our different experimental approaches and the mechanistic complexity we uncovered. Culture methods used in their study probably resulted in BMM-derived populations containing both macrophage lineage cells immature enough to form osteoclasts and macrophages mature enough to mediate inhibitory actions, and indeed, perhaps cells with both properties. Nevertheless, our work suggests that whatever the responding cells are, IL-33 action would involve autocrine/paracrine production of GM-CSF and Th 2 cytokines. Schulze et al. also did not find that IL-33 affected osteoblast matrix mineral deposition as we consistently did. The reasons for this are unclear, and it remains to be seen whether this is due to a difference in the constitution of the osteoblastic populations used. It should be noted the osteoblast stimulation protocols in our two studies differed, e.g. the much higher ␤-glycerophosphate concentrations used by Schulze et al., which can greatly increase diffuse calcification (i.e. that not associated with nodules) and render increases in mineralized nodule formation difficult to confirm by Alizarin red elution. However, the significance of these differences remains to be determined.
Although our studies and those of Schulze et al. (53) indicated that IL-33 inhibits osteoclast formation (weak induction of RANKL mRNA in osteoblasts notwithstanding), with no direct stimulating action on BMM cells in the absence of RANKL, Mun et al. (34) reported that IL-33 has strong RANKL-independent effects on stimulating osteoclast differentiation from human progenitors. We also studied human osteoclast formation but found little evidence for a strong stimulatory activity in our GM-CFU cells. IL-33 did elicit formation of TRAP ϩ mononuclear cells, and resorption pits were identified on the dentine substrates, but this was small compared with the thousands of pits seen in RANKLstimulated cultures. It is possible our cultures differ significantly from those of Mun et al., perhaps in terms of contaminating lymphocytes or progenitor responsiveness to IL-33. We used progenitors expanded in vitro before RANKL stimulus, which differentiate more rapidly than monocyte cultures. This is an important technicality because monocytes cultured for 2 or more weeks can form activated macrophages expressing TRAP, vitronectin receptor, and other characteristics found in osteoclasts and can fuse; it is notable that Mun et al. (34) observed significant TRAP ϩ MNC formation in the absence of both RANKL and IL-33. To study bone resorption, an osteoclast specific trait, an artificial resorption substrate was used; however, such substrates may be resorbed by macrophages (unlike intact bone or dentine), making definitive conclusions difficult. Thus, these observations with human monocytes, although suggestive and interesting, need further detailed confirmation.
IL-33 effects in bone in vivo are difficult to investigate due to strong proinflammatory effects of systemic administration (14) , although it is likely these and other immune system-related effects significantly influence bone, at least in pathological lesions. This will doubtless be clarified by further study of ST2 and IL-33 null mice. IL-33 production by cardiac fibroblasts under elevated mechanical stress in heart failure (26) may also suggest mechanical stress-related actions in bone.
In summary, we have confirmed IL-33 as an endogenous, regulated factor in osteoblasts. The actions of IL-33 are in general antiosteoclastogenic and proosteoblastic, the latter possibly involving suppression of sclerostin expression in osteocytes. This combination of properties suggests that encouraging local osteoblast expression of IL-33 (at least below levels evoking inflammatory or mast cell recruitment) may increase bone mass.
